SR-9009

updated

SR-9009 is a synthetic REV-ERB agonist marketed for endurance, fat loss and metabolic conditioning, often stacked with cardarine, and a 2025 editorial pairs it with the trade name Stenabolic. The evidence is mouse and cell data only, and the REV-ERB mechanism behind it is disputed. No controlled human study exists: a PubMed search on 10 October 2026 for SR9009 with clinical trial filters returned 0 records, and ClinicalTrials.gov returned no studies.

REV-ERB agonist (research compound)

  • SR9009 is PubChem CID 57394020, C20H24ClN3O4S, molecular weight 437.9; the trade name Stenabolic was not among the first 12 PubChem synonyms.
  • In mice exposed to constant light for 8 weeks, SR9009 at 10 mg/kg daily reduced weight gain, insulin resistance and white fat mass; the route is not stated, and this is prevention of gain in a circadian-disruption model, not fat loss in lean animals or in people.
  • A 2024 paper reports that SR9009 and two analogues improved exercise tolerance in normal mice; dose and route are not in the abstract.
  • In a 2019 REV-ERB alpha and beta double deletion model, SR9009 still decreased cell viability and altered transcription in cells lacking both proteins, so its effects are not treated as REV-ERB effects.
  • No oral bioavailability, plasma concentration or half-life of SR9009 was found in any species, and DailyMed returned no label.
  • Of 44 products bought online in 2016 and marketed as SARMs, 17 (39%) contained a different unapproved drug, among them ibutamoren, GW501516 and SR9009.

What is SR-9009, and what is its regulatory status?

SR-9009 is a synthetic REV-ERB agonist from mouse and cell research, paired in print with the trade name Stenabolic. DailyMed returned no label and ClinicalTrials.gov no study, and the name alone does not settle what is in a given vial.

SR9009 is PubChem CID 57394020, C20H24ClN3O4S, molecular weight 437.9, CAS 1379686-30-2, chemically ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate. Listed synonyms include SR-9009 and SR 9009. Stenabolic was not among the first 12 PubChem synonyms.

A 2025 journal editorial pairs the names as Stenabolic (SR9009), so the trade name is tied to the compound in print. But one case report classifies Stenabolic as a SARM, and products sold online as SARMs have contained SR9009. The name alone does not settle what is in a given vial.

DailyMed returned no labels for SR9009 or stenabolic, and ClinicalTrials.gov queries for SR9009, stenabolic and REV-ERB agonist returned no studies. WADA list status was not established in the sources reviewed, and status outside the United States is not covered here.

PubChem: SR9009 identity

Chemical identity record

PubChem, National Library of Medicine. Compound summary for CID 57394020, SR9009.

SR9009 is PubChem CID 57394020, C20H24ClN3O4S, 437.9 g/mol, CAS 1379686-30-2, IUPAC name ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate. Listed synonyms include SR-9009 and SR 9009. Stenabolic was not among the first 12 PubChem synonyms.

Participants / model
Chemical identity, not a clinical population
Treatment
Defined molecule
Follow-up
Not applicable
Study design
Chemical database record
Funding
not stated in the source

Identity record only. A 2025 journal editorial pairs the names as Stenabolic (SR9009) (PMID 40389157), but one case report classifies Stenabolic as a SARM and products sold online as SARMs have contained SR9009, so the name alone does not settle what is in a given vial.

Read the original source
PubMed: 0 trial-type records; no registered study; no label; no study of the cardarine stack

PubMed search record

PubMed search for (SR9009 OR SR-9009 OR stenabolic) AND (clinical trial[pt] OR randomized controlled trial[pt] OR controlled clinical trial[pt]), run 10 October 2026, with ClinicalTrials.gov, DailyMed and combination queries.

A PubMed search on 10 October 2026 for SR9009, SR-9009 or stenabolic with clinical trial, randomized controlled trial or controlled clinical trial publication types returned 0 records. ClinicalTrials.gov queries for SR9009, stenabolic and REV-ERB agonist returned no studies, and DailyMed returned no labels for SR9009 or stenabolic. A PubMed query for SR9009, SR-9009 or stenabolic with GW501516, cardarine or GW1516 returned 5 records: two reviews of exercise mimetics (PMIDs 26439443 and 26658171) whose abstracts name neither compound, and three analytical papers that list both compounds as product contents or screening targets (PMIDs 29183075, 34814052 and 26842585). None describes the two given together to animals or people.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Searches run on 10 October 2026
Study design
Dated literature, registry and label search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source
44 internet products: 17 held a different unapproved drug, among them SR9009

Chemical identity record

Van Wagoner RM et al. JAMA. 2017;318(20):2004-2010. PMID 29183075.

Of 44 products bought online in 2016 that were marketed as SARMs, 23 (52%) contained one or more SARMs (ostarine, LGD-4033 or andarine). Another 17 (39%) contained a different unapproved drug, among them ibutamoren, GW501516 and the Rev-ErbA agonist SR9009. Substances not on the label were found in 11 (25%), and labeled amounts differed substantially from analysis in 26 (59%). The abstract does not say how many products held SR9009.

Participants / model
44 internet products
Treatment
Commercial supplements and powders
Follow-up
Products bought in 2016
Study design
Original analytical study
Funding
not stated in the source

Product content, not a human outcome study. The count of products holding SR9009 is not in the abstract.

Read the original source

What did the mouse and cell studies find?

SR9009 improved exercise tolerance in normal mice and, in mice exposed to constant light, reduced weight gain and white fat mass. A founding 2012 mouse report found less obesity with a REV-ERB agonist, and no controlled human study exists.

The founding report is a 2012 mouse paper on synthetic REV-ERB agonists with in vivo activity. They altered circadian behavior and the circadian pattern of core clock gene expression in the hypothalamus, altered circadian expression of metabolic genes in liver, skeletal muscle and adipose tissue, and increased energy expenditure. In diet-induced obese mice a REV-ERB agonist decreased obesity by reducing fat mass and markedly improved dyslipidemia and hyperglycemia. The abstract does not name SR9009, a dose or a route, so none of this is attributed to SR9009 specifically.

A 2024 medicinal chemistry paper reports that SR9009 and two analogues (5m and 5p) improved exercise tolerance in normal mice in vivo. In hyperlipidemic mice, 5m and 5p also lowered blood lipids and showed stronger hypoglycemic activity than SR9009. Dose and route are not in the abstract. A 2013 paper reported that pharmacological activation of Rev-erb-alpha in vivo increased exercise capacity in mice, without naming the compound in its abstract.

In mice exposed to constant light for 8 weeks, chronic low-dose SR9009 (10 mg/kg daily) reduced weight gain, insulin resistance and white fat mass, with no significant impact on overall energy homeostasis. It suppressed Bmal1 and restored Rev-erb alpha and beta expression in white and brown adipose tissue, and it inhibited adipogenesis in 3T3-L1 cells. This is prevention of gain in a circadian-disruption model, not fat loss in lean animals or in people, and the route is not in the abstract.

2012 mouse report on REV-ERB agonists; SR9009 not named in the abstract

Animal study

Solt LA et al. Nature. 2012;485(7396):62-8. PMID 22460951.

Synthetic REV-ERB agonists with in vivo activity altered circadian behavior and the circadian pattern of core clock gene expression in the hypothalamus, altered circadian expression of metabolic genes in liver, skeletal muscle and adipose tissue, and increased energy expenditure. In diet-induced obese mice a REV-ERB agonist decreased obesity by reducing fat mass and markedly improved dyslipidemia and hyperglycemia. The abstract does not name SR9009, a dose or a route.

Participants / model
Mice, including diet-induced obese mice
Treatment
Synthetic REV-ERB agonists; compound, dose and route not stated in the abstract
Follow-up
not stated in the source
Study design
Original preclinical study
Funding
not stated in the source

The founding mouse report behind the metabolic claims. Because the abstract does not name SR9009, compound-specific wording would need the full text.

Read the original source
2024 paper: exercise tolerance in normal mice, lipids in hyperlipidemic mice

Animal study

Li L et al. Bioorg Med Chem. 2024;111:117845. PMID 39059249.

A 2024 medicinal chemistry paper reports that SR9009 and two analogues (5m and 5p) improved exercise tolerance in normal mice in vivo. In hyperlipidemic mice, 5m and 5p also lowered blood lipids and showed stronger hypoglycemic activity than SR9009. Dose and route are not in the abstract.

Participants / model
Normal and hyperlipidemic mice
Treatment
SR9009 and analogues 5m and 5p; dose and route not stated in the abstract
Follow-up
not stated in the source
Study design
Original medicinal chemistry and preclinical study
Funding
not stated in the source

Mouse endurance finding for SR9009. Exercise tolerance in mice is not endurance performance in people.

Read the original source
2013 paper: Rev-erb-alpha activation raised exercise capacity in mice

Animal study

Woldt E et al. Nat Med. 2013;19(8):1039-46. PMID 23852339.

A 2013 paper reported that pharmacological activation of Rev-erb-alpha in vivo increased exercise capacity in mice, without naming the compound in its abstract.

Participants / model
Mice
Treatment
Pharmacological Rev-erb-alpha activation; compound, dose and route not stated in the abstract
Follow-up
not stated in the source
Study design
Original preclinical study
Funding
not stated in the source

The abstract does not name SR9009, so the result is not attributed to it.

Read the original source
Constant-light mice, 8 weeks: less weight gain and white fat; 3T3-L1 adipogenesis inhibited

Animal study

Yang MY et al. Biomed J. 2025;48(3):100830. PMID 39800061.

In mice exposed to constant light for 8 weeks, chronic low-dose SR9009 (10 mg/kg daily) reduced weight gain, insulin resistance and white fat mass, with no significant impact on overall energy homeostasis. It suppressed Bmal1 and restored Rev-erb alpha and beta expression in white and brown adipose tissue, and it inhibited adipogenesis in 3T3-L1 cells.

Participants / model
Mice under constant light; 3T3-L1 cells
Treatment
SR9009 at 10 mg/kg daily for 8 weeks; route not stated in the abstract
Follow-up
8 weeks
Study design
Original preclinical study, mouse model and cell culture
Funding
not stated in the source

Prevention of gain in a circadian-disruption model, not fat loss in lean animals or in people.

Read the original source

How does SR-9009 act, and is REV-ERB the whole story?

SR-9009 is described as a REV-ERB agonist, and the 2012 mouse work behind the metabolic claims concerns synthetic REV-ERB agonists. Later work shows SR9009 still acts in cells and mice lacking REV-ERB alpha and beta, so its published effects are SR9009 effects and not REV-ERB effects.

In a conditional REV-ERB alpha and beta double deletion model, SR9009 still decreased cell viability, rewired cellular metabolism and altered gene transcription in hepatocytes and embryonic stem cells lacking both proteins, so the authors conclude its effects cannot be used solely as a surrogate for REV-ERB activity (2019).

Two later studies agree. SR9009's cardioprotection after pressure overload was retained in cardiac-specific REV-ERB alpha and beta double knockout mice, and in prostate cancer cells REV-ERB knockdown or knockout did not rescue its effect, which ran through LXR alpha instead.

Published effects of SR9009 are therefore described here as SR9009 effects, not as REV-ERB effects. The 2012 abstract and the 2013 exercise paper do not name SR9009, and none of the mouse abstracts states a route.

2019 double deletion model: SR9009 still acts without REV-ERB

Cell study

Dierickx P et al. Proc Natl Acad Sci U S A. 2019;116(25):12147-12152. PMID 31127047.

In a conditional REV-ERB alpha and beta double deletion model, SR9009 still decreased cell viability, rewired cellular metabolism and altered gene transcription in hepatocytes and embryonic stem cells lacking both proteins, so the authors conclude its effects cannot be used solely as a surrogate for REV-ERB activity (2019).

Participants / model
Mouse hepatocytes and embryonic stem cells lacking REV-ERB alpha and beta
Treatment
SR9009 in cell culture; concentration not stated in the abstract
Follow-up
not stated in the source
Study design
Original preclinical study, conditional double deletion model
Funding
not stated in the source

Published effects of SR9009 should be described as SR9009 effects, not as REV-ERB effects.

Read the original source
Cardioprotection kept in REV-ERB double knockout mice

Animal study

Li H et al. Front Cardiovasc Med. 2022;9:952114. PMID 35911512.

SR9009's cardioprotection after pressure overload was retained in cardiac-specific REV-ERB alpha and beta double knockout mice.

Participants / model
Cardiac-specific REV-ERB alpha and beta double knockout mice
Treatment
SR9009; in vivo route not stated in the abstract
Follow-up
not stated in the source
Study design
Original preclinical study
Funding
not stated in the source

Agrees with the 2019 finding that SR9009 acts independently of REV-ERB.

Read the original source
Prostate cancer cells: effect ran through LXR alpha, not REV-ERB

Cell study

Xu H et al. Cell Death Dis. 2022;13(11):949. PMID 36357378.

In prostate cancer cells, REV-ERB knockdown or knockout did not rescue the effect of SR9009, which ran through LXR alpha instead.

Participants / model
Human prostate cancer cells
Treatment
SR9009 in cell culture; concentration not stated in the abstract
Follow-up
not stated in the source
Study design
Original preclinical study
Funding
not stated in the source

Cited here only for what it shows about the mechanism, not for any cancer claim.

Read the original source
2012 mouse report on REV-ERB agonists; SR9009 not named in the abstract

Animal study

Solt LA et al. Nature. 2012;485(7396):62-8. PMID 22460951.

Synthetic REV-ERB agonists with in vivo activity altered circadian behavior and the circadian pattern of core clock gene expression in the hypothalamus, altered circadian expression of metabolic genes in liver, skeletal muscle and adipose tissue, and increased energy expenditure. In diet-induced obese mice a REV-ERB agonist decreased obesity by reducing fat mass and markedly improved dyslipidemia and hyperglycemia. The abstract does not name SR9009, a dose or a route.

Participants / model
Mice, including diet-induced obese mice
Treatment
Synthetic REV-ERB agonists; compound, dose and route not stated in the abstract
Follow-up
not stated in the source
Study design
Original preclinical study
Funding
not stated in the source

The founding mouse report behind the metabolic claims. Because the abstract does not name SR9009, compound-specific wording would need the full text.

Read the original source

Has SR-9009 been tested in people?

No. A PubMed search on 10 October 2026 for SR9009, SR-9009 or stenabolic with clinical trial filters returned 0 records, ClinicalTrials.gov queries returned no studies and DailyMed returned no labels. No oral bioavailability, plasma concentration or half-life of SR9009 was found in any species.

A PubMed search on 10 October 2026 for SR9009, SR-9009 or stenabolic with clinical trial, randomized controlled trial or controlled clinical trial publication types returned 0 records. ClinicalTrials.gov queries for SR9009, stenabolic and REV-ERB agonist returned no studies, and DailyMed returned no labels for SR9009 or stenabolic.

A PubMed query for SR9009 with pharmacokinetics, half-life, oral bioavailability, poor bioavailability or in vivo exposure returned 8 records. Their abstracts, plus three other SR9009 abstracts, were searched for bioavailability, oral, gavage, half-life and pharmacokinetic, and none reports oral bioavailability, plasma concentration or half-life of SR9009 in any species. A 2026 paper on SR9009 metabolism in camel liver says in vivo pharmacokinetics and detection windows are future work. A 2026 paper calls STL1267 a next-generation REV-ERB alpha agonist with improved potency, specificity and pharmacokinetic properties, with no figures in its abstract.

A PubMed query for SR9009, SR-9009 or stenabolic with GW501516, cardarine or GW1516 returned 5 records: two reviews of exercise mimetics whose abstracts name neither compound, and three analytical papers that list both compounds as product contents or screening targets. None describes the two given together to animals or people.

PubMed: 0 trial-type records; no registered study; no label; no study of the cardarine stack

PubMed search record

PubMed search for (SR9009 OR SR-9009 OR stenabolic) AND (clinical trial[pt] OR randomized controlled trial[pt] OR controlled clinical trial[pt]), run 10 October 2026, with ClinicalTrials.gov, DailyMed and combination queries.

A PubMed search on 10 October 2026 for SR9009, SR-9009 or stenabolic with clinical trial, randomized controlled trial or controlled clinical trial publication types returned 0 records. ClinicalTrials.gov queries for SR9009, stenabolic and REV-ERB agonist returned no studies, and DailyMed returned no labels for SR9009 or stenabolic. A PubMed query for SR9009, SR-9009 or stenabolic with GW501516, cardarine or GW1516 returned 5 records: two reviews of exercise mimetics (PMIDs 26439443 and 26658171) whose abstracts name neither compound, and three analytical papers that list both compounds as product contents or screening targets (PMIDs 29183075, 34814052 and 26842585). None describes the two given together to animals or people.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Searches run on 10 October 2026
Study design
Dated literature, registry and label search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source
PubMed: 8 records, none reports bioavailability, plasma level or half-life

PubMed search record

PubMed search for SR9009 AND (pharmacokinetics OR half-life OR oral bioavailability OR poor bioavailability OR in vivo exposure), run 10 October 2026.

A PubMed query on 10 October 2026 for SR9009 with pharmacokinetics, half-life, oral bioavailability, poor bioavailability or in vivo exposure returned 8 records. Their abstracts, plus three other SR9009 abstracts, were searched for bioavailability, oral, gavage, half-life and pharmacokinetic, and none reports oral bioavailability, plasma concentration or half-life of SR9009 in any species. A 2026 paper on SR9009 metabolism in camel liver says in vivo pharmacokinetics and detection windows are future work (PMID 42530886). A 2026 paper calls STL1267 a next-generation REV-ERB alpha agonist with improved potency, specificity and pharmacokinetic properties, with no figures in its abstract (PMID 41512274).

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature search
Funding
not stated in the source

An absence finding as of 10 October 2026, based on abstracts only, not proof that no pharmacokinetic data exist.

Read the original source

Does SR-9009 improve endurance, fat loss or metabolic conditioning?

Only as mouse findings. SR9009 improved exercise tolerance in normal mice and reduced weight gain and white fat in constant-light mice, and a REV-ERB agonist reduced obesity in diet-induced obese mice. No human efficacy or oral bioavailability data exist, the REV-ERB mechanism behind the effects is disputed, and no study of a cardarine stack exists.

Sellers market SR-9009 for endurance, fat loss and metabolic conditioning, often stacked with cardarine. In mice, SR9009 improved exercise tolerance in normal animals and reduced weight gain and white fat mass in mice exposed to constant light. A REV-ERB agonist that the abstract does not name reduced obesity in diet-induced obese mice.

None of this was measured in a person. The constant-light result is prevention of weight gain in a circadian-disruption model, not fat loss in lean animals or in people, and later work disputes the REV-ERB mechanism behind the findings.

No study gave SR9009 and cardarine together to animals or people. A PubMed query for the pair returned 5 records, none of which describes the two given together.

2024 paper: exercise tolerance in normal mice, lipids in hyperlipidemic mice

Animal study

Li L et al. Bioorg Med Chem. 2024;111:117845. PMID 39059249.

A 2024 medicinal chemistry paper reports that SR9009 and two analogues (5m and 5p) improved exercise tolerance in normal mice in vivo. In hyperlipidemic mice, 5m and 5p also lowered blood lipids and showed stronger hypoglycemic activity than SR9009. Dose and route are not in the abstract.

Participants / model
Normal and hyperlipidemic mice
Treatment
SR9009 and analogues 5m and 5p; dose and route not stated in the abstract
Follow-up
not stated in the source
Study design
Original medicinal chemistry and preclinical study
Funding
not stated in the source

Mouse endurance finding for SR9009. Exercise tolerance in mice is not endurance performance in people.

Read the original source
Constant-light mice, 8 weeks: less weight gain and white fat; 3T3-L1 adipogenesis inhibited

Animal study

Yang MY et al. Biomed J. 2025;48(3):100830. PMID 39800061.

In mice exposed to constant light for 8 weeks, chronic low-dose SR9009 (10 mg/kg daily) reduced weight gain, insulin resistance and white fat mass, with no significant impact on overall energy homeostasis. It suppressed Bmal1 and restored Rev-erb alpha and beta expression in white and brown adipose tissue, and it inhibited adipogenesis in 3T3-L1 cells.

Participants / model
Mice under constant light; 3T3-L1 cells
Treatment
SR9009 at 10 mg/kg daily for 8 weeks; route not stated in the abstract
Follow-up
8 weeks
Study design
Original preclinical study, mouse model and cell culture
Funding
not stated in the source

Prevention of gain in a circadian-disruption model, not fat loss in lean animals or in people.

Read the original source
2012 mouse report on REV-ERB agonists; SR9009 not named in the abstract

Animal study

Solt LA et al. Nature. 2012;485(7396):62-8. PMID 22460951.

Synthetic REV-ERB agonists with in vivo activity altered circadian behavior and the circadian pattern of core clock gene expression in the hypothalamus, altered circadian expression of metabolic genes in liver, skeletal muscle and adipose tissue, and increased energy expenditure. In diet-induced obese mice a REV-ERB agonist decreased obesity by reducing fat mass and markedly improved dyslipidemia and hyperglycemia. The abstract does not name SR9009, a dose or a route.

Participants / model
Mice, including diet-induced obese mice
Treatment
Synthetic REV-ERB agonists; compound, dose and route not stated in the abstract
Follow-up
not stated in the source
Study design
Original preclinical study
Funding
not stated in the source

The founding mouse report behind the metabolic claims. Because the abstract does not name SR9009, compound-specific wording would need the full text.

Read the original source
2019 double deletion model: SR9009 still acts without REV-ERB

Cell study

Dierickx P et al. Proc Natl Acad Sci U S A. 2019;116(25):12147-12152. PMID 31127047.

In a conditional REV-ERB alpha and beta double deletion model, SR9009 still decreased cell viability, rewired cellular metabolism and altered gene transcription in hepatocytes and embryonic stem cells lacking both proteins, so the authors conclude its effects cannot be used solely as a surrogate for REV-ERB activity (2019).

Participants / model
Mouse hepatocytes and embryonic stem cells lacking REV-ERB alpha and beta
Treatment
SR9009 in cell culture; concentration not stated in the abstract
Follow-up
not stated in the source
Study design
Original preclinical study, conditional double deletion model
Funding
not stated in the source

Published effects of SR9009 should be described as SR9009 effects, not as REV-ERB effects.

Read the original source
PubMed: 0 trial-type records; no registered study; no label; no study of the cardarine stack

PubMed search record

PubMed search for (SR9009 OR SR-9009 OR stenabolic) AND (clinical trial[pt] OR randomized controlled trial[pt] OR controlled clinical trial[pt]), run 10 October 2026, with ClinicalTrials.gov, DailyMed and combination queries.

A PubMed search on 10 October 2026 for SR9009, SR-9009 or stenabolic with clinical trial, randomized controlled trial or controlled clinical trial publication types returned 0 records. ClinicalTrials.gov queries for SR9009, stenabolic and REV-ERB agonist returned no studies, and DailyMed returned no labels for SR9009 or stenabolic. A PubMed query for SR9009, SR-9009 or stenabolic with GW501516, cardarine or GW1516 returned 5 records: two reviews of exercise mimetics (PMIDs 26439443 and 26658171) whose abstracts name neither compound, and three analytical papers that list both compounds as product contents or screening targets (PMIDs 29183075, 34814052 and 26842585). None describes the two given together to animals or people.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Searches run on 10 October 2026
Study design
Dated literature, registry and label search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source

What do laboratory analyses show about SR-9009 products and its metabolism?

Of 44 products bought online in 2016 and marketed as SARMs, 17 contained a different unapproved drug, among them SR9009, and labeled amounts differed substantially from analysis in 26. Liver microsome work found 8 to 13 SR9009 metabolites, and these are in vitro findings, not human exposure data.

Of 44 products bought online in 2016 that were marketed as SARMs, 23 (52%) contained one or more SARMs (ostarine, LGD-4033 or andarine). Another 17 (39%) contained a different unapproved drug, among them ibutamoren, GW501516 and the Rev-ErbA agonist SR9009. Substances not on the label were found in 11 (25%), and labeled amounts differed substantially from analysis in 26 (59%). The abstract does not say how many products held SR9009. A Ghent doping control laboratory (2016) also found SR9009 in a black market product bought over the internet.

The same Ghent laboratory detected eight metabolites of SR9009 (and fourteen of SR9011) in human liver microsome assays, and found neither parent compound nor metabolites in 1511 routine doping control samples analyzed retrospectively. It recommends adding both compounds to screening methods. A 2018 study found SR9009 was biotransformed to 13 metabolites in human liver microsomes by CYP3A4, CYP3A5, CYP2C19 and CYP2D6, with de-alkylated metabolites most abundant, no significant sex difference, differences by CYP2D6 and CYP2C19 variants, and significant changes with ketoconazole, miconazole, fluoxetine, nefazodone and paroxetine.

These are in vitro metabolism and analytical findings. Human excretion data, detection windows and WADA list status are not established in the sources reviewed. A 2021 hair screening method includes SR9009 (PMID 34814052).

44 internet products: 17 held a different unapproved drug, among them SR9009

Chemical identity record

Van Wagoner RM et al. JAMA. 2017;318(20):2004-2010. PMID 29183075.

Of 44 products bought online in 2016 that were marketed as SARMs, 23 (52%) contained one or more SARMs (ostarine, LGD-4033 or andarine). Another 17 (39%) contained a different unapproved drug, among them ibutamoren, GW501516 and the Rev-ErbA agonist SR9009. Substances not on the label were found in 11 (25%), and labeled amounts differed substantially from analysis in 26 (59%). The abstract does not say how many products held SR9009.

Participants / model
44 internet products
Treatment
Commercial supplements and powders
Follow-up
Products bought in 2016
Study design
Original analytical study
Funding
not stated in the source

Product content, not a human outcome study. The count of products holding SR9009 is not in the abstract.

Read the original source
Ghent doping laboratory: product found, 8 metabolites, 0 of 1511 samples positive

Chemical identity record

Geldof L et al. Int J Mol Sci. 2016;17(10). PMID 27706103.

A Ghent doping control laboratory (2016) found SR9009 in a black market product bought over the internet, detected eight metabolites of SR9009 (and fourteen of SR9011) in human liver microsome assays, and found neither parent compound nor metabolites in 1511 routine doping control samples analyzed retrospectively. It recommends adding both compounds to screening methods.

Participants / model
Human liver microsomes; one internet product; 1511 routine doping control samples
Treatment
In vitro assays; mass spectrometry of a product and of samples
Follow-up
not stated in the source
Study design
Original analytical study
Funding
not stated in the source

In vitro metabolism and analytical findings. Human excretion data and detection windows are not in the abstract. Related analytical work includes certified reference materials for two human SR9009 metabolites (PMID 30129998), a 2021 hair screening method that includes SR9009 (PMID 34814052) and a 2016 review listing SR9009 among REV-ERB agonists that could be misused in sport (PMID 26842585).

Read the original source
13 metabolites; CYP3A4, 3A5, 2C19 and 2D6; changes with five inhibitors

Cell study

Mazzarino M et al. Drug Test Anal. 2018;10(11-12):1670-1681. PMID 30395700.

A 2018 study found SR9009 was biotransformed to 13 metabolites in human liver microsomes by CYP3A4, CYP3A5, CYP2C19 and CYP2D6, with de-alkylated metabolites most abundant, no significant sex difference, differences by CYP2D6 and CYP2C19 variants, and significant changes with ketoconazole, miconazole, fluoxetine, nefazodone and paroxetine.

Participants / model
Human liver microsomes
Treatment
SR9009 incubated with human liver microsomes; concentration not stated in the abstract
Follow-up
not stated in the source
Study design
Original in vitro study
Funding
not stated in the source

In vitro metabolism only. No human interaction or excretion data.

Read the original source

What is known about the safety of SR-9009?

No human safety study exists. The only human report is one case of hepatocellular liver injury in a 40-year-old man after a product called Stenabolic, with its contents unconfirmed and attribution resting on the authors' judgment. Pharmacokinetics are unknown, and in vitro work shows several CYP enzymes metabolize SR9009.

A 40-year-old man taking multiple over-the-counter supplements developed hepatocellular liver injury soon after starting Stenabolic. Infectious and autoimmune causes were ruled out, the authors thought Stenabolic the likely source, and he improved after stopping, with supportive care. The report calls Stenabolic a SARM and compares it to anabolic steroids, which conflicts with SR9009's identity as a REV-ERB agonist, and the abstract describes no analysis of what the product contained. It is one case, with attribution resting on the authors' judgment.

No oral bioavailability, plasma concentration or half-life of SR9009 has been reported in any species, so exposure is unknown. In human liver microsomes, metabolism of SR9009 by CYP3A4, CYP3A5, CYP2C19 and CYP2D6 changed significantly with ketoconazole, miconazole, fluoxetine, nefazodone and paroxetine. That is an in vitro finding with no human interaction data.

In a 2016 analysis of 44 products marketed as SARMs, labeled amounts differed substantially from analysis in 26, and SR9009 was among the unapproved drugs found. The identity and amount of material sold under the name cannot be assumed.

Case report: 40-year-old man, hepatocellular injury, improved after stopping

Case report

Govil D et al. Cureus. 2025;17(7):e87376. PMID 40765588.

A 40-year-old man taking multiple over-the-counter supplements developed hepatocellular liver injury soon after starting Stenabolic. Infectious and autoimmune causes were ruled out, Stenabolic was thought the likely source, and he improved after stopping, with supportive care. The report calls Stenabolic a SARM and compares it to anabolic steroids, and the abstract describes no analysis of what the product contained.

Participants / model
A 40-year-old man
Treatment
Self-administered Stenabolic product, contents not stated
Follow-up
not stated in the source
Study design
Single case report
Funding
not stated in the source

The only human safety report found. The SARM label conflicts with SR9009's identity as a REV-ERB agonist, and attribution rests on the authors' judgment.

Read the original source
PubMed: 8 records, none reports bioavailability, plasma level or half-life

PubMed search record

PubMed search for SR9009 AND (pharmacokinetics OR half-life OR oral bioavailability OR poor bioavailability OR in vivo exposure), run 10 October 2026.

A PubMed query on 10 October 2026 for SR9009 with pharmacokinetics, half-life, oral bioavailability, poor bioavailability or in vivo exposure returned 8 records. Their abstracts, plus three other SR9009 abstracts, were searched for bioavailability, oral, gavage, half-life and pharmacokinetic, and none reports oral bioavailability, plasma concentration or half-life of SR9009 in any species. A 2026 paper on SR9009 metabolism in camel liver says in vivo pharmacokinetics and detection windows are future work (PMID 42530886). A 2026 paper calls STL1267 a next-generation REV-ERB alpha agonist with improved potency, specificity and pharmacokinetic properties, with no figures in its abstract (PMID 41512274).

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature search
Funding
not stated in the source

An absence finding as of 10 October 2026, based on abstracts only, not proof that no pharmacokinetic data exist.

Read the original source
13 metabolites; CYP3A4, 3A5, 2C19 and 2D6; changes with five inhibitors

Cell study

Mazzarino M et al. Drug Test Anal. 2018;10(11-12):1670-1681. PMID 30395700.

A 2018 study found SR9009 was biotransformed to 13 metabolites in human liver microsomes by CYP3A4, CYP3A5, CYP2C19 and CYP2D6, with de-alkylated metabolites most abundant, no significant sex difference, differences by CYP2D6 and CYP2C19 variants, and significant changes with ketoconazole, miconazole, fluoxetine, nefazodone and paroxetine.

Participants / model
Human liver microsomes
Treatment
SR9009 incubated with human liver microsomes; concentration not stated in the abstract
Follow-up
not stated in the source
Study design
Original in vitro study
Funding
not stated in the source

In vitro metabolism only. No human interaction or excretion data.

Read the original source
44 internet products: 17 held a different unapproved drug, among them SR9009

Chemical identity record

Van Wagoner RM et al. JAMA. 2017;318(20):2004-2010. PMID 29183075.

Of 44 products bought online in 2016 that were marketed as SARMs, 23 (52%) contained one or more SARMs (ostarine, LGD-4033 or andarine). Another 17 (39%) contained a different unapproved drug, among them ibutamoren, GW501516 and the Rev-ErbA agonist SR9009. Substances not on the label were found in 11 (25%), and labeled amounts differed substantially from analysis in 26 (59%). The abstract does not say how many products held SR9009.

Participants / model
44 internet products
Treatment
Commercial supplements and powders
Follow-up
Products bought in 2016
Study design
Original analytical study
Funding
not stated in the source

Product content, not a human outcome study. The count of products holding SR9009 is not in the abstract.

Read the original source

Why does SR-9009 sit in D tier?

D fits mouse and cell data only, a founding mechanism that later work shows does not fully explain the effects, no human efficacy or bioavailability data, and one case report of liver injury after a product of unconfirmed identity. It is not graded F because that report cannot tie the injury to SR9009 and nothing else in the records reviewed documents human harm.

SR-9009 has mouse findings for exercise tolerance and for weight gain and white fat, a founding 2012 mechanism that later work shows does not fully explain its effects, and no human efficacy or oral bioavailability data. It has also been the subject of doping-control screening work and has turned up in products sold as SARMs. SR-9011, the same class with the same kind of evidence, is also graded D on this site.

It is not graded F because the one case report of liver injury cannot tie the injury to SR9009, since the product's contents were not analyzed, and nothing else in the records reviewed documents human harm.

2012 mouse report on REV-ERB agonists; SR9009 not named in the abstract

Animal study

Solt LA et al. Nature. 2012;485(7396):62-8. PMID 22460951.

Synthetic REV-ERB agonists with in vivo activity altered circadian behavior and the circadian pattern of core clock gene expression in the hypothalamus, altered circadian expression of metabolic genes in liver, skeletal muscle and adipose tissue, and increased energy expenditure. In diet-induced obese mice a REV-ERB agonist decreased obesity by reducing fat mass and markedly improved dyslipidemia and hyperglycemia. The abstract does not name SR9009, a dose or a route.

Participants / model
Mice, including diet-induced obese mice
Treatment
Synthetic REV-ERB agonists; compound, dose and route not stated in the abstract
Follow-up
not stated in the source
Study design
Original preclinical study
Funding
not stated in the source

The founding mouse report behind the metabolic claims. Because the abstract does not name SR9009, compound-specific wording would need the full text.

Read the original source
2019 double deletion model: SR9009 still acts without REV-ERB

Cell study

Dierickx P et al. Proc Natl Acad Sci U S A. 2019;116(25):12147-12152. PMID 31127047.

In a conditional REV-ERB alpha and beta double deletion model, SR9009 still decreased cell viability, rewired cellular metabolism and altered gene transcription in hepatocytes and embryonic stem cells lacking both proteins, so the authors conclude its effects cannot be used solely as a surrogate for REV-ERB activity (2019).

Participants / model
Mouse hepatocytes and embryonic stem cells lacking REV-ERB alpha and beta
Treatment
SR9009 in cell culture; concentration not stated in the abstract
Follow-up
not stated in the source
Study design
Original preclinical study, conditional double deletion model
Funding
not stated in the source

Published effects of SR9009 should be described as SR9009 effects, not as REV-ERB effects.

Read the original source
PubMed: 0 trial-type records; no registered study; no label; no study of the cardarine stack

PubMed search record

PubMed search for (SR9009 OR SR-9009 OR stenabolic) AND (clinical trial[pt] OR randomized controlled trial[pt] OR controlled clinical trial[pt]), run 10 October 2026, with ClinicalTrials.gov, DailyMed and combination queries.

A PubMed search on 10 October 2026 for SR9009, SR-9009 or stenabolic with clinical trial, randomized controlled trial or controlled clinical trial publication types returned 0 records. ClinicalTrials.gov queries for SR9009, stenabolic and REV-ERB agonist returned no studies, and DailyMed returned no labels for SR9009 or stenabolic. A PubMed query for SR9009, SR-9009 or stenabolic with GW501516, cardarine or GW1516 returned 5 records: two reviews of exercise mimetics (PMIDs 26439443 and 26658171) whose abstracts name neither compound, and three analytical papers that list both compounds as product contents or screening targets (PMIDs 29183075, 34814052 and 26842585). None describes the two given together to animals or people.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Searches run on 10 October 2026
Study design
Dated literature, registry and label search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source
Case report: 40-year-old man, hepatocellular injury, improved after stopping

Case report

Govil D et al. Cureus. 2025;17(7):e87376. PMID 40765588.

A 40-year-old man taking multiple over-the-counter supplements developed hepatocellular liver injury soon after starting Stenabolic. Infectious and autoimmune causes were ruled out, Stenabolic was thought the likely source, and he improved after stopping, with supportive care. The report calls Stenabolic a SARM and compares it to anabolic steroids, and the abstract describes no analysis of what the product contained.

Participants / model
A 40-year-old man
Treatment
Self-administered Stenabolic product, contents not stated
Follow-up
not stated in the source
Study design
Single case report
Funding
not stated in the source

The only human safety report found. The SARM label conflicts with SR9009's identity as a REV-ERB agonist, and attribution rests on the authors' judgment.

Read the original source
PubMed: 8 records, none reports bioavailability, plasma level or half-life

PubMed search record

PubMed search for SR9009 AND (pharmacokinetics OR half-life OR oral bioavailability OR poor bioavailability OR in vivo exposure), run 10 October 2026.

A PubMed query on 10 October 2026 for SR9009 with pharmacokinetics, half-life, oral bioavailability, poor bioavailability or in vivo exposure returned 8 records. Their abstracts, plus three other SR9009 abstracts, were searched for bioavailability, oral, gavage, half-life and pharmacokinetic, and none reports oral bioavailability, plasma concentration or half-life of SR9009 in any species. A 2026 paper on SR9009 metabolism in camel liver says in vivo pharmacokinetics and detection windows are future work (PMID 42530886). A 2026 paper calls STL1267 a next-generation REV-ERB alpha agonist with improved potency, specificity and pharmacokinetic properties, with no figures in its abstract (PMID 41512274).

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature search
Funding
not stated in the source

An absence finding as of 10 October 2026, based on abstracts only, not proof that no pharmacokinetic data exist.

Read the original source

Studies and sources

PubChem: SR9009 identity

Chemical identity record

PubChem, National Library of Medicine. Compound summary for CID 57394020, SR9009.

SR9009 is PubChem CID 57394020, C20H24ClN3O4S, 437.9 g/mol, CAS 1379686-30-2, IUPAC name ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate. Listed synonyms include SR-9009 and SR 9009. Stenabolic was not among the first 12 PubChem synonyms.

Participants / model
Chemical identity, not a clinical population
Treatment
Defined molecule
Follow-up
Not applicable
Study design
Chemical database record
Funding
not stated in the source

Identity record only. A 2025 journal editorial pairs the names as Stenabolic (SR9009) (PMID 40389157), but one case report classifies Stenabolic as a SARM and products sold online as SARMs have contained SR9009, so the name alone does not settle what is in a given vial.

Read the original source
2012 mouse report on REV-ERB agonists; SR9009 not named in the abstract

Animal study

Solt LA et al. Nature. 2012;485(7396):62-8. PMID 22460951.

Synthetic REV-ERB agonists with in vivo activity altered circadian behavior and the circadian pattern of core clock gene expression in the hypothalamus, altered circadian expression of metabolic genes in liver, skeletal muscle and adipose tissue, and increased energy expenditure. In diet-induced obese mice a REV-ERB agonist decreased obesity by reducing fat mass and markedly improved dyslipidemia and hyperglycemia. The abstract does not name SR9009, a dose or a route.

Participants / model
Mice, including diet-induced obese mice
Treatment
Synthetic REV-ERB agonists; compound, dose and route not stated in the abstract
Follow-up
not stated in the source
Study design
Original preclinical study
Funding
not stated in the source

The founding mouse report behind the metabolic claims. Because the abstract does not name SR9009, compound-specific wording would need the full text.

Read the original source
2024 paper: exercise tolerance in normal mice, lipids in hyperlipidemic mice

Animal study

Li L et al. Bioorg Med Chem. 2024;111:117845. PMID 39059249.

A 2024 medicinal chemistry paper reports that SR9009 and two analogues (5m and 5p) improved exercise tolerance in normal mice in vivo. In hyperlipidemic mice, 5m and 5p also lowered blood lipids and showed stronger hypoglycemic activity than SR9009. Dose and route are not in the abstract.

Participants / model
Normal and hyperlipidemic mice
Treatment
SR9009 and analogues 5m and 5p; dose and route not stated in the abstract
Follow-up
not stated in the source
Study design
Original medicinal chemistry and preclinical study
Funding
not stated in the source

Mouse endurance finding for SR9009. Exercise tolerance in mice is not endurance performance in people.

Read the original source
2013 paper: Rev-erb-alpha activation raised exercise capacity in mice

Animal study

Woldt E et al. Nat Med. 2013;19(8):1039-46. PMID 23852339.

A 2013 paper reported that pharmacological activation of Rev-erb-alpha in vivo increased exercise capacity in mice, without naming the compound in its abstract.

Participants / model
Mice
Treatment
Pharmacological Rev-erb-alpha activation; compound, dose and route not stated in the abstract
Follow-up
not stated in the source
Study design
Original preclinical study
Funding
not stated in the source

The abstract does not name SR9009, so the result is not attributed to it.

Read the original source
Constant-light mice, 8 weeks: less weight gain and white fat; 3T3-L1 adipogenesis inhibited

Animal study

Yang MY et al. Biomed J. 2025;48(3):100830. PMID 39800061.

In mice exposed to constant light for 8 weeks, chronic low-dose SR9009 (10 mg/kg daily) reduced weight gain, insulin resistance and white fat mass, with no significant impact on overall energy homeostasis. It suppressed Bmal1 and restored Rev-erb alpha and beta expression in white and brown adipose tissue, and it inhibited adipogenesis in 3T3-L1 cells.

Participants / model
Mice under constant light; 3T3-L1 cells
Treatment
SR9009 at 10 mg/kg daily for 8 weeks; route not stated in the abstract
Follow-up
8 weeks
Study design
Original preclinical study, mouse model and cell culture
Funding
not stated in the source

Prevention of gain in a circadian-disruption model, not fat loss in lean animals or in people.

Read the original source
2019 double deletion model: SR9009 still acts without REV-ERB

Cell study

Dierickx P et al. Proc Natl Acad Sci U S A. 2019;116(25):12147-12152. PMID 31127047.

In a conditional REV-ERB alpha and beta double deletion model, SR9009 still decreased cell viability, rewired cellular metabolism and altered gene transcription in hepatocytes and embryonic stem cells lacking both proteins, so the authors conclude its effects cannot be used solely as a surrogate for REV-ERB activity (2019).

Participants / model
Mouse hepatocytes and embryonic stem cells lacking REV-ERB alpha and beta
Treatment
SR9009 in cell culture; concentration not stated in the abstract
Follow-up
not stated in the source
Study design
Original preclinical study, conditional double deletion model
Funding
not stated in the source

Published effects of SR9009 should be described as SR9009 effects, not as REV-ERB effects.

Read the original source
Cardioprotection kept in REV-ERB double knockout mice

Animal study

Li H et al. Front Cardiovasc Med. 2022;9:952114. PMID 35911512.

SR9009's cardioprotection after pressure overload was retained in cardiac-specific REV-ERB alpha and beta double knockout mice.

Participants / model
Cardiac-specific REV-ERB alpha and beta double knockout mice
Treatment
SR9009; in vivo route not stated in the abstract
Follow-up
not stated in the source
Study design
Original preclinical study
Funding
not stated in the source

Agrees with the 2019 finding that SR9009 acts independently of REV-ERB.

Read the original source
Prostate cancer cells: effect ran through LXR alpha, not REV-ERB

Cell study

Xu H et al. Cell Death Dis. 2022;13(11):949. PMID 36357378.

In prostate cancer cells, REV-ERB knockdown or knockout did not rescue the effect of SR9009, which ran through LXR alpha instead.

Participants / model
Human prostate cancer cells
Treatment
SR9009 in cell culture; concentration not stated in the abstract
Follow-up
not stated in the source
Study design
Original preclinical study
Funding
not stated in the source

Cited here only for what it shows about the mechanism, not for any cancer claim.

Read the original source
Ghent doping laboratory: product found, 8 metabolites, 0 of 1511 samples positive

Chemical identity record

Geldof L et al. Int J Mol Sci. 2016;17(10). PMID 27706103.

A Ghent doping control laboratory (2016) found SR9009 in a black market product bought over the internet, detected eight metabolites of SR9009 (and fourteen of SR9011) in human liver microsome assays, and found neither parent compound nor metabolites in 1511 routine doping control samples analyzed retrospectively. It recommends adding both compounds to screening methods.

Participants / model
Human liver microsomes; one internet product; 1511 routine doping control samples
Treatment
In vitro assays; mass spectrometry of a product and of samples
Follow-up
not stated in the source
Study design
Original analytical study
Funding
not stated in the source

In vitro metabolism and analytical findings. Human excretion data and detection windows are not in the abstract. Related analytical work includes certified reference materials for two human SR9009 metabolites (PMID 30129998), a 2021 hair screening method that includes SR9009 (PMID 34814052) and a 2016 review listing SR9009 among REV-ERB agonists that could be misused in sport (PMID 26842585).

Read the original source
13 metabolites; CYP3A4, 3A5, 2C19 and 2D6; changes with five inhibitors

Cell study

Mazzarino M et al. Drug Test Anal. 2018;10(11-12):1670-1681. PMID 30395700.

A 2018 study found SR9009 was biotransformed to 13 metabolites in human liver microsomes by CYP3A4, CYP3A5, CYP2C19 and CYP2D6, with de-alkylated metabolites most abundant, no significant sex difference, differences by CYP2D6 and CYP2C19 variants, and significant changes with ketoconazole, miconazole, fluoxetine, nefazodone and paroxetine.

Participants / model
Human liver microsomes
Treatment
SR9009 incubated with human liver microsomes; concentration not stated in the abstract
Follow-up
not stated in the source
Study design
Original in vitro study
Funding
not stated in the source

In vitro metabolism only. No human interaction or excretion data.

Read the original source
Case report: 40-year-old man, hepatocellular injury, improved after stopping

Case report

Govil D et al. Cureus. 2025;17(7):e87376. PMID 40765588.

A 40-year-old man taking multiple over-the-counter supplements developed hepatocellular liver injury soon after starting Stenabolic. Infectious and autoimmune causes were ruled out, Stenabolic was thought the likely source, and he improved after stopping, with supportive care. The report calls Stenabolic a SARM and compares it to anabolic steroids, and the abstract describes no analysis of what the product contained.

Participants / model
A 40-year-old man
Treatment
Self-administered Stenabolic product, contents not stated
Follow-up
not stated in the source
Study design
Single case report
Funding
not stated in the source

The only human safety report found. The SARM label conflicts with SR9009's identity as a REV-ERB agonist, and attribution rests on the authors' judgment.

Read the original source
44 internet products: 17 held a different unapproved drug, among them SR9009

Chemical identity record

Van Wagoner RM et al. JAMA. 2017;318(20):2004-2010. PMID 29183075.

Of 44 products bought online in 2016 that were marketed as SARMs, 23 (52%) contained one or more SARMs (ostarine, LGD-4033 or andarine). Another 17 (39%) contained a different unapproved drug, among them ibutamoren, GW501516 and the Rev-ErbA agonist SR9009. Substances not on the label were found in 11 (25%), and labeled amounts differed substantially from analysis in 26 (59%). The abstract does not say how many products held SR9009.

Participants / model
44 internet products
Treatment
Commercial supplements and powders
Follow-up
Products bought in 2016
Study design
Original analytical study
Funding
not stated in the source

Product content, not a human outcome study. The count of products holding SR9009 is not in the abstract.

Read the original source
PubMed: 0 trial-type records; no registered study; no label; no study of the cardarine stack

PubMed search record

PubMed search for (SR9009 OR SR-9009 OR stenabolic) AND (clinical trial[pt] OR randomized controlled trial[pt] OR controlled clinical trial[pt]), run 10 October 2026, with ClinicalTrials.gov, DailyMed and combination queries.

A PubMed search on 10 October 2026 for SR9009, SR-9009 or stenabolic with clinical trial, randomized controlled trial or controlled clinical trial publication types returned 0 records. ClinicalTrials.gov queries for SR9009, stenabolic and REV-ERB agonist returned no studies, and DailyMed returned no labels for SR9009 or stenabolic. A PubMed query for SR9009, SR-9009 or stenabolic with GW501516, cardarine or GW1516 returned 5 records: two reviews of exercise mimetics (PMIDs 26439443 and 26658171) whose abstracts name neither compound, and three analytical papers that list both compounds as product contents or screening targets (PMIDs 29183075, 34814052 and 26842585). None describes the two given together to animals or people.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Searches run on 10 October 2026
Study design
Dated literature, registry and label search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source

Why is SR-9009 in D tier?

D fits a compound with mouse and cell data only, a founding mechanism that later work shows does not fully explain its effects, no human efficacy or bioavailability data, and one case report of liver injury after a product of unconfirmed identity. It is not graded F because that report cannot tie the injury to SR9009 and nothing else in the records reviewed documents human harm.